<DOC>
	<DOCNO>NCT00620581</DOCNO>
	<brief_summary>The efficacy SSRI use relieve symptom associate premenstrual dysphoric disorder establish . We propose test hypothesis intermittent treatment paroxetine administer luteal phase menstrual cycle effective placebo improve symptom PMDD . This double-blind , placebo-controlled , three-arm parallel group study patient PMDD . Menstruating woman 18 year age old meet criterion inclusion study randomize one three arm : paroxetine 10mg/day luteal phase menstrual cycle ; paroxetine 20mg/day luteal phase menstrual cycle ; placebo daily luteal phase menstrual cycle . The objective evaluate efficacy safety intermittent treatment paroxetine woman PMDD .</brief_summary>
	<brief_title>Luteal Phase Administration Paroxetine Treatment PMDD</brief_title>
	<detailed_description />
	<mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>PMDD accord DSMIV criterion Women exclude take oral contraception , breastfeeding , pregnant , plan become pregnant study period . Women also exclude meet DSMIV criterion Axis I disorder , deem suicidal risk , history SSRI use premenstrual symptom , take ongoing medication could affect PMDD symptom , clinically significant abnormality screen blood test , baseline MontgomeryAsberg Depression Rating Scale score equal great 10 follicular phase menstrual cycle .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2005</verification_date>
</DOC>